|
Market Closed -
Saudi Arabian S.E.
15:20:00 15/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 65.40 SAR | -2.39% |
|
-2.53% | +2.92% |
| 08-27 | Avalon Pharma Reiterated at Overweight as Aljazira Capital Notes 'Solid' Q2 Growth | MT |
| 08-20 | Avalon Pharma Renews SAR50 Million Credit Facility | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Generic Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 624M | - | - | - | - | - |
| 46.06B | |||||
| 38.29B | |||||
| 11.65B | |||||
| 11.51B | |||||
| 9.17B |
Select your edition
All financial news and data tailored to specific country editions
